The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4 mg (24/4-day regimen) in obese users Article

sustainable development goals

publication date

  • December 1, 2023

webpage

published in

keywords

  • Bleeding profile
  • Drospirenone
  • Obesity
  • Oral contraceptive
  • Pearl Index
  • Progestin-only pill
  • Safety

volume

  • 128